Abstract
To the Editor: In a recent article in the Journal by Basu et al. the usefulness of monitoring heparin therapy by the activated partial thromboplastin time (APTT) is emphasized.1 The authors recommend that patients with venous thromboembolism be given doses of heparin that prolong the APTT to between 1.5 and 2.5 times control levels. However, Soloway et al. emphasize that “… optimal ranges of heparin anticoagulation must be defined in terms of the products used in the performance of APTT's, and that ranges established with one product cannot be interchanged when using another manufacturer's reagents.”2 Moreover, Lenahan and Phillips have.
Original language | English |
---|---|
Pages (from-to) | 1410 |
Number of pages | 1 |
Journal | New England Journal of Medicine |
Volume | 288 |
Issue number | 26 |
DOIs | |
Publication status | Published - 28 Jun 1973 |